Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
ST Kim, J Lee, JH Kim, YW Won, JM Sun… - …, 2010 - mdanderson.elsevierpure.com
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
[引用][C] Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy
STAE KIM, J LEE, JH KIM, YW WON, JM SUN, J YUN - Cancer, 2010 - pascal-francis.inist.fr
Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who
Failed Previous Chemotherapy CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Failed Previous Chemotherapy CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[PDF][PDF] Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy
ST Kim, J Lee, J Kim, YW Won, J Sun, J Yun - Cancer, 2010 - academia.edu
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
ST Kim, J Lee, J Kim, YW Won, JM Sun, J Yun, YH Park… - Cancer, 2010 - infona.pl
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
ST Kim, J Lee, JH Kim, YW Won, JM Sun, J Yun… - Cancer, 2010 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib and erlotinib are commonly used for salvage therapy in patients with
nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although both …
nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although both …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
ST Kim, J Lee, JH Kim, YW Won, JM Sun, J Yun… - Cancer, 2010 - europepmc.org
Background Gefitinib and erlotinib are commonly used for salvage therapy in patients with
nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although both …
nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although both …
Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy
ST Kim, J Lee, JH Kim, YW Won, JM Sun, J Yun… - …, 2010 - scholarworks.bwise.kr
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy
ST Kim, J Lee, J Kim, YW Won, J Sun, J Yun… - …, 2010 - scholarworks.bwise.kr
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …